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Abstract
Hepatitis C virus (HCV) is endemic worldwide, and it causes cirrhosis and other complications that often lead to
death; nevertheless, our knowledge of the disease and its mechanisms is limited. HCV is most common in
underdeveloped nations, including many in Africa and Asia. The virus is usually transmitted by parenteral routes,
but sexual, perinatal, and other types of transfer have been known to occur. Approximately 80% of individuals who
contract hepatitis C develop a chronic infection, and very few are able to spontaneously clear the virus. Because
hepatitis C is asymptomatic in the majority of patients, the presence of HCV RNA in the serum is the best
diagnostic tool. Although serious complications from hepatitis C may not occur for 20 years, 1/5 of chronic
patients eventually develop life - threatening cirrhosis. More research is needed on the different therapy options
for the disease, and many factors, most importantly the genotype of the virus, must be taken into account before
beginning any treatment. As there is no vaccine against HCV at present, the most effective and recommended
therapy is pegylated-interferon-a-2a plus ribavirin. While interferon is marginally effective as a monotherapy, both
adding the moiety and combining it with ribavirin have been shown to dramatically increase its potency. While
there are numerous alternative and complementary medicines available for patients with hepatitis C, their efficacy
is questionable. Currently, research is being done to investigate other possible treatments for hepatitis C, and
progress is being made to develop a vaccine against HCV, despite the many challenges the virus presents. Until
such a vaccination is available, prevention and control methods are important in containing and impeding the
spread of the virus and mitigating its deleterious effects on the health of people and communities worldwide.
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Introduction
The hepatitis C virus (HCV) infects up to 170 million
people throughout the world, causing chronic liver dis-
ease, inflammation, and long-term complications [1-3].
HCV is a member of the Flaviviridae family, has single-
stranded RNA, and is relatively small (55 nm - 65 nm)
[1-4]. In 1989, it was determined that HCV is responsible
for most transfusion-associated non-A and non-B hepati-
tis infections [2,5]. Eleven different genotypes of the virus
have been identified, each with various subtypes and
strains, but 60% of HCV infections are caused by type 1a
and type 1b [1,5]. The majority of those exposed to HCV
become chronic carriers of the virus; only 20% - 30% are
expected to be free of the virus within six months of
infection [1,3,6]. Nearly 20% of chronic carriers develop
cirrhosis, while another 20% develop liver cancer [1],
(Figure 1). HCV is also the leading cause of hepatocellu-
lar carcinoma and cirrhosis [5].
Acute and chronic hepatitis C
The severity of hepatitis C ranges from mild, short-term
symptoms to complicated, life-long liver disease that can
result in death. Whether the infection is acute or
becomes chronic depends on the duration of the virus’
existence in the patient’s body.
Acute hepatitis C is a short-term infection of the virus
that occurs during the first six months after exposure to
HCV. The acute stage of the disease is characterized by
elevated serum alanine aminotransferase (ALT) levels and
jaundice, which appears in about 25% of cases [1,5,7].
About 80% of acute hepatitis C cases are asymptomatic,
and are therefore difficult to diagnose [5,8]. However, if a
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any medium, provided the original work is properly cited.patient’ss y m p t o m sa n d / o rl i f e s t y le are suggestive of an
HCV infection, they should be tested for the disease. The
presence of HCV RNA in the serum is the most reliable
way to diagnose hepatitis C, but the presence of anti-HCV
antibodies in the serum or an elevated serum ALT level (a
concentration at least ten times the upper limit of the nor-
mal range is necessary for a diagnosis) can also indicate an
HCV infection [1,3,5,7]. The remaining 20% of cases are
symptomatic, and are characterized by poor appetite,
abdominal pain in the right upper quadrant, joint and
muscle pains, nausea, vomiting, and fever [1,3,5,7]. How-
ever, because these symptoms are common and inconclu-
sive, symptomatic hepatitis C should be diagnosed by the
same tests used to confirm an asymptomatic infection.
An acute hepatitis C infection becomes a chronic disease
if the individual is unable to clear the virus from their sys-
tem within six months of infection without any therapeu-
tic intervention; approximately 70% - 80% of those with an
acute infection develop chronic hepatitis C [1,5,6]. Chronic
hepatitis C is officially diagnosed by the presence of anti-
HCV and the elevation of serum ALT levels for more than
six months [3]. Even in the chronic stage, however, most
infected persons show no symptoms until serious compli-
cations arise, although this often does not occur until 20
years after infection [1,3,5]. As such complications –
including hepato-cellular carcinoma, liver failure, and cir-
rhosis – develop as the infection progresses, more promi-
nent symptoms such as swelling of the abdomen, fatigue,
dark urine, fluid retention, jaundice, ascites, muscle weak-
ness, itching, and weight loss are observed [3,5]. Cirrhosis
is perhaps the most well known consequence of chronic
hepatitis C, and occurs in about 20% of patients [1,5].
About 20% - 25% of patients who do develop cirrhosis as a
result of HCV die from liver failure [5].
Treatment of hepatitis C
The goal of hepatitis C treatment is to prevent the
development of chronic infection, increase the patient’s
Figure 1 Progression of HCV Infection.
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However, the type and duration of therapy a patient
receives depends on a number of factors, including age,
the genotype of the virus, and any previous conditions
the patient may have. For example, individuals with
decompensated cirrhosis, severe uncontrolled psychiatric
disorders, advanced cardiovascular or cerebrovascular
disease, creatinine clearance of less than 50 mL/min, or
women who are pregnant should not receive therapy
[3,9,10]. Additionally, more research is needed on the
proper treatment protocol for children, which is likely
different than that for adults [11,12].
So far, 11 HCV genotypes have been discovered, but
only genotypes 1, 2 and 3 are distributed worldwide,
and about 60% of infections are due to type 1a and 1b
[1,5]. The genotype of the virus plays a substantial role
in determining the duration and type of treatment the
patient receives (viral load of serum is the other main
factor to consider); thus it is necessary to confirm the
g e n o t y p eo fas p e c i f i ci n f ection in order to plan an
appropriate therapeutic strategy [2,3,5]. Although all
genotypes exhibit relatively equal virulence, they differ
in their response to a given medication [1-5]. In general,
any treatment involving Interferon (IFN) is more effec-
tive against HCV genotype 2 and 3 than against geno-
type 1, which is less responsive to therapy [1-5]. Thus, a
48-week course of treatment is recommended for geno-
type 1, whereas a 24-week therapy is sufficient for geno-
types 2 and 3 [2,3,5].
Non-pharmacologic treatments
After a patient is diagnosed with hepatitis C, lifestyle
changes must be made in order to limit and control
further health problems. These non-pharmacologic
treatments include engaging in regular physical exercise,
adopting healthy eating habits, and maintaining a
healthy weight. The latter is especially important,
because it is believed that obesity in HCV patients plays
a significant role in the progression of fibrosis [13,14].
Also, patients should avoid drinking alcohol because
there is no safe minimum limit of consumption, and
alcohol is one of the major risk factors for liver disease
and exacerbates the negative effects of hepatitis C
[3,15,16]. Additionally, hepatitis C patients are advised
not to smoke because smoking may contribute to the
progression of the disease and increase the likelihood of
developing hepatocellular carcinoma [9,17].
Pharmacologic treatments
Most cases (72%-98%) of symptomatic acute hepatitis C
are curable if diagnosed early [18]. However, because
some patients with symptomatic HCV may sponta-
neously clear the virus from their systems within 12
weeks of infection, therapy should not begin until after
this time period has elapsed in order to avoid unneces-
sary treatment and medical costs [8,18-20]. On the
other hand, because relatively few individuals with
asymptomatic acute hepatitis C are able to sponta-
neously clear the virus, in such cases the appropriate
treatment should be initiated as soon as possible [18,20].
However, the rate of spontaneous clearance is debatable;
some sources indicate that around 31% of symptomatic
cases and about 18% of asymptomatic cases are naturally
resolved without treatment [18], while others suggest
higher figures. A study by Geralch et al., for instance,
showed that permanent and spontaneous clearance of
the virus was observed in more than 50% of untreated
patients with acute symptomatic HCV within the first
three to four months after infection [20]. Those who
remained infected after that time period were treated
with either IFN-monotherapy, or with IFN plus riba-
virin, and about 80% of those patients showed a sus-
tained biochemical and virological response. Initiating
treatment in patients with acute symptomatic HCV
three months after infection led to viral clearance in
91% of the patients as a result of both spontaneous
clearance and anti-viral treatment [20]. Regardless of the
exact figures, there is a general consensus that asympto-
matic patients should begin receiving treatment immedi-
ately, while symptomatic patients may benefit from
postponing therapy for several months.
Pegylated interferon-alpha monotherapy
The covalent attachment of a polyethylene glycol (peg)
moiety to IFN-a reduces the clearance and degradation
of the drug, thus sustaining a high plasma concentration
and prolonging the half-life of the compound, respec-
tively [2,3]. There are currently two versions of this
compound known as pegylated interferon (peg-IFN)
being used to treat hepatitis C: peg-IFN-a-2a and peg-
IFN-a-2b. Common side effects of peg-IFN-a treatment
include headache, fatigue, depression, insomnia, fever,
nausea, myalgia, weakness, hematologic disorder, and
injection site reaction [21]. Studies show that a once
weekly administration of peg-IFN-a-2a is more efficient
than a regimen of IFN-a-2a [22-24]. A comparison
between the clinical effects of a regimen of peg-IFN-a-
2a and a regimen of IFN-a-2a was made in the study by
Z e u z e me ta l .( T a b l e1 ) .T h er e s u l t ss h o wap r o f o u n d
improvement in both virology and biochemical
responses after 48 and 72 weeks [22].
Peg-IFN-a-2a versus Peg-IFN- a-2b
The FDA has approved both pegasys (peg-IFN-a-2a)
and PEG-Intron (peg-IFN-a-2b) for use as monothera-
pies and in combination for the treatment of chronic
HCV in patients with compensated liver disease who
have not been treated previously. Some of the
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Table 2.
Ribavirin
Ribavirin is a synthetic nucleoside antagonist that is
active against a broad range of viruses [27,28]. It hinders
the initiation and elongation of RNA fragments by inhi-
biting the synthesis of viral proteins [4,28]. However, the
mechanism by which it inhibits HCV RNA in combina-
tion therapy with interferon products has not been
established [4,11]. Using ribavirin alone as a monother-
apy for hepatitis C is not recommended, as other treat-
ments (including ribavirin combined with interferon) are
more effective [29-32].
The results of a randomized, double blind, placebo-
controlled study conducted to evaluate the role of riba-
virin in the treatment of chronic hepatitis C showed that
ribavirin monotherapy, given for periods as long as 12
months, is of limited use as a therapy for chronic hepati-
t i sC .I nt h i ss t u d y ,ar a p i dd e c r e a s ei ns e r u ma m i n o -
transferase levels was observed in 54% of patients who
were treated with ribavirin. However, only 7% of patients
had normal levels of aminotransferase after the disconti-
nuation of ribavirin and there was no change in the
serum HCV RNA levels during or after the treatment,
proving that the therapy is ineffective [29]. The outcome
of a study by Dusheiko et al. indicates that there was no
difference between the treatment group and the placebo
group in the reduction of HCV RNA levels six months
after ribavirin therapy was discontinued. As a result, they
concluded that ribavirin was no more effective than a
placebo in the treatment of HCV [30].
Also, ribavirin has several adverse side effects that
make it less preferable over other treatments [32]. For
example, hemolytic anemia is a common consequence
of ribavirin use, but a lower, less-effective dose of the
drug may be necessary to reverse the reduction of
hemoglobin values [9,32]. Other frequent side effects of
ribavirin include pruritus, rash, indigestion, loss of appe-
tite, nausea, headache, and fatigue [11,32].
Pegylated interferon and ribavirin
The highest sustained virologic response (SVR) in
patients with hepatitis C has been achieved by a treat-
ment combining peg-IFN -a-2a and ribavirin. This com-
bination therapy has thus become the current standard
of care for patients with chronic hepatitis C who have
not been treated previously [33].
The findings of a large randomized clinical trial of
1530 patients with chronic hepatitis C show a
Table 1 A summary of the effects of Peg-IFN-a-2a vs. IFN-a-2a. From Zeuzem et al. [22].
End of Treatment Response Peg-IFN-a-2a Group IFN-a-2a Group
No. Patients completed treatment = 223 No. Patients completed treatment = 161
No. Patients completed follow-up = 206 No. Patients completed follow-up = 154
No. % (95% CI) No. % (95% CI)
Response at week 48
Virological 185 69 (63-75) 73 28 (22-33)
Biochemical 123 46 (40-52) 104 39 (33-46)
Both virological and biochemical 109 41 (35-47) 65 25 (20-30)
Response at week 72
Virological 103 39 (33-45) 50 19 (14-24)
Biochemical 120 45 (39-51) 65 25 (20-30)
Both virological and biochemical 101 38 (32-44) 46 17 (13-23)
IFN = Interferon, Peg-IFN = pegylated-Interferon
Table 2 A comparison of Peg-IFN-a-2a and Peg-IFN-a-2b
Peg-IFN-a-2a Peg-IFN-a-2b Remark
Size Large polyethylene
glycol moiety
Relatively small polyethylene
glycol moiety
Polyethylene glycol moiety in Peg-IFN-a-2a is twice the size of
that in Peg-INF-a-2b [9].
Common Dose 180 μg/week
subcutaneously
1.5 μg/kg/wk subcutaneously
Efficacy* Worse Better
Infant and
Neonatal use
Contraindicated Safe Peg-IFN-a-2a contains benzyl alcohol [9].
*The results of a randomized trial suggested that, despite its relatively short half-life, Peg-IFN-a-2b results in a greater decrease in HCV RNA than Peg-IFN-a-2a
during the first four weeks of monotherapy [25]. However, there was no difference observed between Peg-IFN-a-2b plus ribavirin and Peg-IFN-a-2a plus ribavirin
in the treatment of chronic hepatitis C in HIV-infected patients [26]
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virin group than in the IFN-a-2b plus ribavirin group
during initial treatment [34]. This study also established
the dose-dependent nature of peg-IFN: a higher dose
(1.5 g/kg) of peg-IFN given once weekly in combination
with ribavirin is more effective than the lower dose (0.5
g/kg) administered by the same protocol. Patients given
the lower dose also showed a response similar to that of
the patients who received a standard dose of IFN-a-2b
plus ribavirin. Table 3 summarizes the outcomes of the
various treatment groups. Adverse effects were similar
in both the peg-IFN-a-2b plus ribavirin group and in
the IFN-a-2b plus ribavirin group [34].
A randomized, double blind trial with 1311 partici-
pants was conducted to assess the efficacy and safety of
24 versus 48 weeks of treatment with peg-IFN-a-2a a
plus a low or standard dose of ribavirin [35]. The results
showed that the duration of treatment using peg-IFN-a-
2a and ribavirin should be determined based on the
HCV genotype. According to this study, HCV genotype
1 is best treated by a 48-week regimen of 180 μg/wk of
peg-IFN-a-2a and a standard, weight-based dose (1000
or 1200 mg/d) of ribavirin. Another study showed that a
low vitamin D serum level is associated with low
response rates and severe fibrosis in genotype 1 [36].
Therefore, Vitamin D supplementation may increase
sustained response to pegylated interferon plus ribavirin
[37]. HCV genotypes 2 and 3 can be treated adequately
with a 24-week regimen of 180 μg/wk of peg-IFN-a-2a
and a low-dose (800 mg/d) of ribavirin [35].
The response to therapy in HCV patients is heterozy-
gous and, despite increases in SVR rates, treatment out-
comes in certain populations with peg-IFN-a and
ribavirin are not optimal and may still be improved
[35,38]. Early antiviral response to therapy should be
monitored to assist in identifying patients who are less
likely to achieve SVR and is therefore critical in the
management of HCV patients. Rapid virological
response (RVR) and complete early virological response
(cEVR) are linked with patients who achieve SVR [39].
Identifying both patient- and virus-related baseline and
treatment factors that are associated with RVR and
cEVR with peg-IFN-a-2a plus ribavirin therapy may
help predict a patient’s response to treatment, in addi-
tion to supplying information that can be used to
enhance viral outcomes [39,40]. For example, adjusting
baseline and/or treatment factors, such as drug dose,
may increase a patient’s chance of a successful response
to therapy. Moreover, those patients unlikely to reach
RVR or cEVR will be recognized early on and this will
diminish needless healthcare expenses and side-effects.
A retrospective analysis demonstrated that factors
including lower serum HCV RNA concentration,
absence of cirrhosis, higher ALT quotient, younger age,
white non-Latino ethnicity, and daily on-treatment riba-
virin dose > 13 mg/kg were independently linked with
achieving RVR and cEVR in patients with HCV geno-
type 1 and treated with peg-IFN-a-2a plus ribavirin for
48 weeks [41]. They recommended that physicians
maintain a higher ribavirin dose in patients to increase
the likelihood of achieving SVR and tailoring treatment
r e g i m e n sb a s e do na ni n d i v i d u a l ’s risk profile may be
one approach to achieve optimal antiviral response.
Protease inhibitors
One of the most important determents of response to
therapy is the genetic profile of the patient. Patients
with a polymorphic mutation on the IL-28B gene for
genotype 1 have poor response to treatment. Currently
the standard for care is the combination of peg-IFN-a
and ribavirin, but only 40-50% of patients infected with
HCV genotype 1 have SVR [35]. Retreatment only
achieves SVR in 10-20% of patients, but data released at
the International Liver Congress shows SVR rates of 40-
80% when protease inhibitors are used, even in the pre-
sence of the IL-28B genotype [42-44].
Telaprevir
Telaprevir (VX-950) is a targeted antiviral therapy for
hepatitis C. This drug is administered orally and selec-
tively and reversibly inhibits HCV NS3/4A protease, an
enzyme required for viral replication. Studies show that
VX-950 has a significant antiviral effect on patients with
HCV genotype 1, and is well tolerated [45-47]. It has a
synergistic antiviral effect when administered with IFN
as demonstrated in several studies [47]. Telaprevir was
FDA-approved in May, 2011 after the results of the
ADVANCE trial [48]. This trial showed that telaprevir
combined with standard therapy cured the virus in 75%
of patients compared with 44% of patients who were
Table 3 Virological responses in the study by Manns et al. [34]
Groups Overall SVR SVR at end of follow-up SVR by genotype
GT 1 GT 2/3 GT 4/5/6
Higher-dose peg-IFN + Rib 65% P < 0.001 54% P = 0.01 42% 82% 50%
Lower-dose peg-IFN + Rib 56%, P = 0.41 47% P = 0.73 34% 80% 33%
IFN + Rib 54% 47% 33% 79% 38%
INF = Interferon, Rib = Ribavirin, SVR = sustained virologic response, GT = genotype. *P values are calculated for comparison with IFN + Rib
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telaprevir -treated patients who had undetectable viral
levels at weeks 4 and 12 and who were eligible by the
terms of the study to receive 24 weeks total of treatment
- half the time required for standard treatment -
approximately 90% were cured. There were also sub-
stantial benefits of telaprevir in subgroups of patients
who generally do not respond well to standard therapy.
For example, only 25% of African-Americans treated
with standard therapy achieved a viral cure compared to
62% of African-American patients who reached a viral
cure with the telaprevir regimen. In another group of
patients with advanced liver cirrhosis 62% achieved a
viral cure with telaprevir versus 33% on standard ther-
apy [48]. These results confirm the findings of the U.S.
P h a s e2P R O V E1s t u d ya n dt h eE u r o p e a nP R O V E2
study [46].
Boceprevir
Boceprevir, (SCH 503034), is a peptidomimetic ketoa-
mide HCV NS3 protease inhibitor that binds reversibly
to the NS3 active site [49]. It has potential as a time-
dependent inhibitor of the NS3 protease in cell-free
enzyme assays, and has shown robust in vitro activity
in the HCV replicon system. The use of SCH 503034
in combination with IFN was more effective than
either therapy alone in inhibiting viral replication [50].
Boceprevir has also been shown to minimize the emer-
gence of resistant HCV strains when combined with
the inhibitor HCV-796 [49], and was approved by the
FDA in May, 2011. The HCV RESPOND-2 study
looked at 403 chronic hepatitis C patients with geno-
type 1 who still had significant levels of the virus after
standard treatment of peginterferon and ribavirin. Sig-
nificantly more patients were cured with boceprevir
than with peginterferon and ribavirin [51]. A second
study, HACV SPRINT-2, examined patients with
chronic HCV genotype 1 infection who had not yet
undergone standard treatment, and it was found that
there were significantly increased rates of sustained
virologic response [52].
Although these direct anti-virals are effective in the
treatment of both treatment-naïve HCV patients and
those patients who were previously unresponsive to cur-
rent treatment options, the development of resistant
viral variants may be cause for worry. Two studies have
found HCV strains resistant to these novel antiviral
compounds even for patients who had never been pre-
viously exposed to the new antiviral compounds [53-55].
Each new copy of the HCV genome exhibits on average
one nucleotide change per replication cycle; this allows
the virus to quickly come up with mutations that render
it resistant to antiviral drugs. This is a major concern
for successful anti-HCV therapy [56].
A significant number of HIV patients are also infected
with HCV. With improved survival rates in the HIV
population liver disease caused by HCV becomes a ser-
ious issue in the health and survival of these patients
[57]. HCV patients who are co-infected with HIV have
an increased risk of accelerated end stage liver disease
and hepatocellular carcinoma than patients infected only
with HCV. Therefore treatment should be considered a
priority in this group [58]. In October, 2011 the Eur-
opean AIDS Clinical Society (EACS) and the American
Association for the Study of Liver Diseases (AASLD)
added telaprevir and boceprevir in their guidelines for
HIV/HCV co-infected patients [59,60].
There are several other antiviral drugs in different
phases of clinical trials. Table 4 summarizes the current
drugs that are under development [61].
Pharmacoeconomics of HCV Therapy
Since the treatment of HCV with peg-IFN and ribavirin is
expensive, it is necessary to evaluate the cost-effective-
ness of the available treatment options. The wholesale
price of a 48-week supply of peg-IFN plus ribavirin is
about $30,000, while a comparable supply of nonpegy-
lated IFN plus ribavirin costs between $15,000 and
$20,000 [9]. A study by Salmon et al. examined the cost-
effectiveness and benefits of the current treatments for a
chronic hepatitis C infection in asymptomatic and HCV
seropositive individuals. The outcome of the study
showed that the cost of therapy depends on the genotype
and the gender of the patients [62]. Another systematic
review of several randomized clinical trials, reports, and
meta-analyses reinforced the cost effectiveness of initial
combination therapy to prolong life, and improve quality
of life [63]. Generally, before beginning treatment, a thor-
ough evaluation of the appropriateness of the therapy is
needed, and all decisions regarding the treatment should
be made by the patient. Malone et al. compared the cost-
effectiveness of treatment with peg-IFN-a-2b plus riba-
virin with that of peg-IFN-a-2a in hypothetical cohorts
of 100 chronic HCV patients, 75% of whom had a geno-
type 1 infection [64]. According to the study, the use of
peg-IFN-a-2b and ribavirin may be cheaper than peg-
IFN-a-2a for the treatment of the hypothetical cohort.
New research has also determined that patients in the
United States with HCV are twice as likely not to have
health insurance as patients without HCV. Only a third
of HCV infected Americans have access to antiviral
therapy. The remaining patients are either not candi-
dates for therapy owing to treatment contraindications
or are uninsured [65].
Future treatment options
Despite recent advances in the treatment of chronic
hepatitis C, the current treatment options have been
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is an unmet need for novel, potent, and well-tolerated
anti-HCV drugs. Currently, researchers are investigating
different treatments for HCV, with the hope of finding
more effective and safer therapies; some of the potential
candidates are discussed below.
Cyclophilin inhibitors
Cyclophilins are cyclosporin binding proteins and are clas-
sified as a family of peptidyl-prolyl cis-trans isomerases.
These enzymes catalyze the cis-trans interconversion of
peptide bonds amino-terminal to proline residues, result-
ing in a conformational change in the protein structure.
There are more than 10 subgroups of cyclophilins in
mammals [66]. Medications that inhibit these proteins
may be an effective treatment against hepatitis C infec-
tions. Debio 025 is a cyclophilin B (CyPB) inhibitor taken
orally that blocks HCV replication by inhibiting CyPB, a
cellular cofactor of the NS5B RNA-dependent RNA poly-
merase [66]. It also has also the ability to delay or prevent
HCV from developing resistance against other antiviral
drugs [67]. SCY-635 is a non-immunosuppressive deriva-
tive of cyclophilin A that is also taken orally. In vitro stu-
dies have shown that this drug exhibits synergistic
antiviral activity when administered with INF-a-2b and
additive antiviral activity when given with ribavirin [68].
Immunomodulatory agents
Several toll-like receptor (TLR) agonists are being investi-
gated as possible drugs to stimulate protective antiviral
immunity. A phase 1 study of CPG 10101, a synthetic oligo-
deoxynucleotide, demonstrated that it acts as an immuno-
modulator and decreases HCV RNA levels [69]. Isatoribine
is a TLR7 agonist that produces a significant dose-dependent
drop in plasma HCV RNA without major side effects [70].
Thiazolides
Studies have noted that thiazolides, such as nitazoxanide
and tizoxanide, are potent inhibitors of HCV replication,
and suggest that thiazolides may enhance current or
future anti-hepatitis treatments [71-73].
Vaccines
At the present, there is not an effective vaccine
against HCV [5], and efforts to develop a vaccine have
been met with many difficulties [1,3,5]. The genetic
diversity among the HCV genotypes makes it challen-
ging to create a single vaccine effective against all
types of the virus [1,3,5], and its fast mutation rate
further complicates the issue [4]. Nevertheless, find-
ings from various studies show promising advances in
the development of new immunotherapy treatments
against HCV.
HCV-LP
An animal study showed that immunization with hepati-
tis C virus-like particles (HCV-LPs) results in the induc-
tion of certain HCV-specific cellular immune responses
that can control a hepatitis C virus infection in chim-
panzees [74]. Another study in baboons found that after
a course of treatment with HCV-LPs all the animals
exhibited an HCV-specific immune response and devel-
oped antibodies to HCV proteins [75].
rDNA and adenovirus vaccines
The induction of long-term HCV-specific antibody and T-
cell responses was demonstrated in chimpanzees as a
result of immunization with recombinant DNA and ade-
novirus vaccines expressing HCV core, E1E2, and NS3-5
genes; a substantial reduction in the viral load was also
observed [76].
Table 4 A summary of current Hepatitis C drugs based on proteases, polymerase, and other degrading enzymes that
are in preclinical development or in clinical trials
Drug Name Pharma Co. Class Clinical Trial Phase
TMC435350 Tibotec & Medivir Protease inhibitor II
R1626 Roche Nucleoside polymerase inhibitor II
DEBIO-025 Debiopharm Cyclophilin inhibitor II
Celgosivir Migenix a-glucosidase inhibitor II
BI12202 Boehringer Protease inhibitor I
MK-7009 Merck Protease inhibitor I
ITMN-191 InterMune & Roche Protease inhibitor I
NIM-811 Novartis Cyclophilin inhibitor I
R7128 Pharmasset & Roche Nucleoside polymerase inhibitor I
PSI-6130 Pharmasset Nucleoside polymerase inhibitor I
MK-0608 Merck Nucleoside polymerase inhibitor Preclinical
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NS3 protein
This is a new immunization approach using dendritic
cells, the most potent antigen presenting cells, loaded
with viral antigens to induce antiviral immunity [77,78].
Other immunomodulatory agents and vaccines are cur-
rently in clinical trials [79].
Prevention and control of HCV
The Centers for Disease Control and Prevention (CDC)
recommend implementing primary and secondary pre-
vention activities in order to control the spread of HCV
[80]. Primary prevention activities include virus inactiva-
tion in blood products, testing organ and tissue donors,
and providing counseling on risk reduction [5,80]. These
activities aim to reduce the risk of contracting HCV
through the main transmission routes, including the use
of contaminated drug needles, engaging in sexual inter-
course with infected persons, and percutaneous expo-
sure to infected blood in the health care and other (e.g.
tattooing and body piercing) fields [80]. Secondary pre-
vention activities, such as counseling, identifying and
testing people at risk, and treating infected patients, are
intended to reduce the risks for liver and other chronic
diseases in those patients infected with HCV [5,80]. Pro-
viding education for healthcare professionals and the
general public, along with surveillance and research to
monitor disease trends are also parts of the comprehen-
sive strategy recommended by the CDC [80].
Conclusions
Although great advances have been made in the devel-
opment of immunotherapies for HCV, this field is chal-
lenged by the lack of adequate knowledge of the virus
and its interaction with the host cells. One of the rea-
sons for these difficulties is the absence of a simple ani-
mal model for the disease, as only chimpanzees can be
used for this purpose. The results of several studies on
the development of effective vaccines and powerful anti-
virals show that more and highly effective protective
treatment options will be available in the near future.
The current standard for care, according to the Ameri-
can Association for the Study of Liver Diseases and Eur-
opean guidelines, is a combination of pegylated IFN and
ribavirin with or without a protease inhibitor in patients
with genotype 1 infection, taking note that these should
be prescribed with caution due to the discovery of resis-
tant strains. Other factors that may influence response
to therapy, such as HDL levels, serum vitamin D levels,
IL-28B genotype, viral load and genotype, and RVR/
cEVR, should be taken into consideration. Implementing
various prevention and control strategies, promptly
identifying and treating acutely infected individuals,
creating public awareness of the disease, and continuing
HCV research should all be of the highest importance.
Recently published phase IIa data for successful HCV
genotype 1 treatment with two antiviral agents for
patients who previously did not respond to peginterferon
and ribavirin therapy
Results reported since peer review of this article showed
a SVR was achieved in HCV genotype 1 patients treated
with only two antiviral agents (asunaprevir and daclatas-
vir), and that a high rate of SVR was obtained when
these two agents were combined with peginterferon
alfa-2a and ribavirin, at 12 weeks after treatment. Nota-
bly, the success rate was 100% in patients receiving the
combination therapy of the two antivirals plus peginter-
feron alfa-2a and ribavirin [81].
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